

NDA 020563/S- 196, 198, and 199  
 NDA 205747/S- 022, 025, and 026

**SUPPLEMENT APPROVAL**

Eli Lilly and Company  
 Attention: Susan D. Sutton, Ph.D.  
 Advisor, Global Regulatory Affairs-US  
 Lilly Corporate Center  
 Indianapolis, IN 46285

Dear Dr. Sutton:

Please refer to your supplemental new drug applications (sNDAs), and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA or the Act) for the following:

| NDA NUMBER | SUPPLEMENT NUMBER | PRODUCT NAME                             | DATE OF SUBMISSION | DATE OF RECEIPT   |
|------------|-------------------|--|--------------------|-------------------|
| 020563     | 196               | Humalog U-100 (insulin lispro injection) | April 2, 2019      | April 2, 2019     |
| 205747     | 022               | Humalog U-200 (insulin lispro injection) | April 2, 2019      | April 2, 2019     |
| 020563     | 198               | Humalog U-100 (insulin lispro injection) | September 5, 2019  | September 5, 2019 |
| 205747     | 025               | Humalog U-200 (insulin lispro injection) | September 5, 2019  | September 5, 2019 |
| 020563     | 199               | Humalog U-100 (insulin lispro injection) | October 2, 2019    | October 2, 2019   |
| 205747     | 026               | Humalog U-200 (insulin lispro injection) | October 2, 2019    | October 2, 2019   |

We also refer to our letter dated September 4, 2019, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for injectable insulins. This information pertains to the risk of cutaneous amyloidosis.

S-196 and 022: These supplemental applications propose the addition of a modified pre-filled insulin pen that can be used with connected devices, mobile applications, or other technology.

S-198 and 025: These Prior Approval supplemental new drug applications provide for updates to the Prescribing Information (PI) and carton labeling to specify that pens be dispensed in the original sealed carton, as requested in our June 20, 2019, Safety-Related Supplement Request letter and consistent with the comments sent to you in our October 10, 2019, correspondence.

S-199 and 026: These supplemental new drug applications provide for revisions to the labeling consistent with our September 4, 2019, letter and the comments sent to you in our October 18, 2019, correspondence.

### **APPROVAL & LABELING**

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling with minor editorial revisions listed below and reflected in the enclosed labeling.

Revision dates and dates for recent major changes were added.

### **WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert, and Instructions for Use), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 020563/S- 196 and 198 and 205747/S-025.**” Approval of this submission by FDA is not required before the labeling is used.

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the Prescribing Information to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>3</sup>

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.<sup>4</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup> For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see FDA.gov.<sup>6</sup>

---

<sup>3</sup> When final, this guidance will represent the FDA's current thinking on this topic. For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

<sup>6</sup> <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Callie Cappel-Lynch, Regulatory Project Manager, at (301) 796-8436.

Sincerely,

*{See appended electronic signature page}*

Patrick Archdeacon, M.D.  
Associate Director for Therapeutics (Acting)  
Division of Metabolism and Endocrinology  
Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

## **ENCLOSURES:**

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert U-100
  - Instructions for Use U-100 KwikPen
  - Instructions for Use U-100 KwikPen Junior
  - Instructions for Use U-100 Tempo Pen
  - Instructions for Use U-100 Vial
  - Patient Package Insert U-200
  - Instructions for Use U-200 KwikPen
- Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

PATRICK ARCHDEACON  
11/15/2019 10:49:03 AM